Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) (ENCORE)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status

Completed

Conditions

Crohn's Disease

Treatments

Biological: Remicade

Study type

Observational

Funder types

Industry

Identifiers

NCT00705614
P03164

Details and patient eligibility

About

Prospective, observational, parallel-group, postmarketing safety surveillance registry in participants treated with Remicade or standard therapy for active or fistulizing Crohn's disease (CD). The follow-up period is up to 5 years. The participants in the standard therapy group may switch over to Remicade any time during the follow-up period

Enrollment

2,662 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

At least 18 years of age, of either sex, and of any race.

Must have active or fistulizing CD and must have experienced at least 1 of the following:

  • failed a tapering regimen of corticosteroids and will be initiating immunosuppressive therapy
  • required corticosteroid treatments for the previous 6 months and will be initiating immunosuppressive therapy
  • luminal or fistulizing CD, which, in the treating physician's judgment, qualifies for initiation of Remicade.
  • Willing to give written informed consent and must be able to adhere to the procedural requirements of the registry.
  • Must be evaluated for active and inactive (latent) tuberculosis (TB) at the Baseline Visit. TB evaluation will consist of TB history questions (eg, medical history, possible previous contact with TB, TB vaccination history). TB evaluation and TB screening (eg, skin test, chest x-ray) are required when a subject starts treatment with Remicade. In these cases, subjects must be screened for TB within 3 months prior to initiating Remicade treatment.

Exclusion criteria

  • Female who is pregnant or nursing.
  • Treated with Remicade prior to Baseline.
  • Previously treated with other tumor necrosis factor (TNF)-active agents and other investigational drugs for CD prior to Baseline.
  • Active or untreated latent TB or other severe infections such as sepsis, abscesses, or opportunistic infections.
  • Moderate or severe heart failure (New York Heart Association [NYHA] Class III: subjects with marked limitation of activity; they are comfortable only at rest/Class IV: subjects who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest).
  • Have lymphoproliferative disorders (eg, lymphoma) or malignancies.
  • In a situation or have any condition that, in the opinion of the treating physician, may interfere with their optimal participation in the registry.
  • Are participating in any other clinical trials (excluding registries).

In addition, subjects will be excluded from treatment with Remicade if any of the criteria listed below are met:

  • Females of childbearing potential unwilling to use a medically accepted method of birth control during treatment with Remicade and to continue its use for at least 6 months after the last Remicade treatment.
  • History of hypersensitivity to murine proteins or to any excipients of Remicade formulation (sucrose, polysorbate 80, monobasic sodium phosphate, and dibasic sodium phosphate).
  • Other conditions that are contraindicated in the Remicade Summary of Product Characteristics (SPC).

Trial design

2,662 participants in 3 patient groups

Remicade Group
Description:
Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
Treatment:
Biological: Remicade
Standard Therapy Group
Description:
Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
Switched to Remicade Group
Description:
Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
Treatment:
Biological: Remicade

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

Ā© Copyright 2024 Veeva Systems